Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

BACKGROUND: In the era of immunotherapy, it is still unclear which is the best first-line therapy for patients with oncogenic driver negative advanced non-squamous non-small cell lung cancer (NS-NSCLC) who cannot tolerate immunotherapy, or subsequent therapy for patients with oncogenic driver positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Le-Tian, Cao, Rui, Wang, Yan-Ru, Sun, Li, Zhang, Xiang-Yan, Guo, Yi-Jia, Zhao, Jian-Zhu, Zhang, Shu-Ling, Jing, Wei, Song, Jun, Han, Cheng-Bo, Ma, Jietao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052669/
https://www.ncbi.nlm.nih.gov/pubmed/33865364
http://dx.doi.org/10.1186/s12885-021-08136-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052669/
https://www.ncbi.nlm.nih.gov/pubmed/33865364
http://dx.doi.org/10.1186/s12885-021-08136-5

Ejemplares similares